All In Biotech

Drug Trial Radar · NCT03740165

Study of Chemotherapy With Pembrolizumab (MK-3475) Followed by Maintenance With Olaparib (MK-7339) for the First-Line Treatment of Women With BRCA Non-mutated Advanced Epithelial Ovarian Cancer (EOC) (MK-7339-001/KEYLYNK-001/ENGOT-ov43/GOG-3036)

A Randomized Phase 3, Double-Blind Study of Chemotherapy With or Without Pembrolizumab Followed by Maintenance With Olaparib or Placebo for the First-Line Treatment of BRCA Non-mutated Advanced Epithelial Ovarian Cancer (EOC) (KEYLYNK-001 / ENGOT-ov43 / GOG-3036)

Last checked: Nov 19, 2026Latest source record: Aug 19, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 1,367 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

1,367

Actual

Start

Dec 18, 2018

Primary completion

Aug 26, 2024

Study completion Apr 14, 2026

Sponsor

Lead sponsor
Merck Sharp & Dohme LLCMerck & Co. (MRK)
Sponsor type
Industry
Collaborators
European Network of Gynaecological Oncological Trial Groups (ENGOT); Gynecologic Oncology Group
First posted
Nov 14, 2018

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
Female only, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to assess the efficacy and safety of treatment with carboplatin/paclitaxel\* PLUS pembrolizumab (MK-3475) and maintenance olaparib (MK-7339) in women with epithelial ovarian cancer (EOC), fallopian tube cancer, or primary peritoneal cancer. The primary study hypotheses are that the combination of pembrolizumab plus carboplatin/paclitaxel\* followed by continued pembrolizumab and maintenance olaparib is superior to carboplatin/paclitaxel alone with respect to Progression Free Survival (PFS) per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) in participants with programmed death-ligand 1 (PD-L1) positive tumors (Combined Positive Score \[CPS\]≥10) and in all participants, and that the combination of pembrolizumab plus carboplatin/paclitaxel followed by continued pembrolizumab is superior to carboplatin/paclitaxel alone with respect to PFS per RECIST 1.1 in participants with PD-L1 positive tumors (CPS≥10) and in all participants.

Conditions

  • Ovarian Cancer
  • Fallopian Tube Cancer
  • Peritoneal Neoplasms

Interventions

  • PembrolizumabBiological

    IV infusion

  • Placebo for pembrolizumabDrug

    IV infusion

  • CarboplatinDrug

    IV infusion

  • PaclitaxelDrug

    IV infusion

  • OlaparibDrug

    Oral tablet

  • Placebo for olaparibDrug

    Oral tablet

  • BevacizumabBiological

    IV infusion

  • DocetaxelDrug

    IV infusion

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Progression-Free Survival (PFS) Per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) as Assessed by the Investigator in Participants With Programmed Death-Ligand 1 (PD-L1) Positive Tumors (Combined Positive Score [CPS]≥10)Time frame: Up to approximately 67 months
  2. PFS Per RECIST 1.1 as Assessed by the Investigator in All ParticipantsTime frame: Up to approximately 67 months

Locations

227 sites in 22 countries. Site status is shown where the registry gives one.

  • University of Alabama at Birmingham (UAB) ( Site 0036)

    Birmingham, Alabama

  • University of Arizona Cancer Center ( Site 0074)

    Tucson, Arizona

  • Disney Family Cancer Center ( Site 0042)

    Burbank, California

  • Kaiser Permanente Oncology Clinical Trial -Oakland ( Site 0077)

    Oakland, California

  • Kaiser Permanente Oncology Clinical Trials-Roseville ( Site 0084)

    Roseville, California

  • Kaiser Permanente Oncology Clinical Trials-Sacramento ( Site 0083)

    Sacramento, California

  • Kaiser Permanente Oncology Clinical Trial - San Francisco ( Site 0078)

    San Francisco, California

  • Kaiser Permanente Oncology Clinical Trial - Santa Clara ( Site 0079)

    Santa Clara, California

  • Kaiser Permanente N. CA Regional Oncology Clinical Trials ( Site 0008)

    Vallejo, California

  • Kaiser Permanente Oncology Clinical Trial - Walnut Creek ( Site 0080)

    Walnut Creek, California

  • Smilow Cancer Center at Yale-New Haven ( Site 0057)

    New Haven, Connecticut

  • Sarasota Memorial Hospital ( Site 0023)

    Sarasota, Florida

  • Emory School of Medicine ( Site 0053)

    Atlanta, Georgia

  • Northeast Georgia Medical Center ( Site 0029)

    Gainesville, Georgia

  • Memorial Health University Medical Center ( Site 0011)

    Savannah, Georgia

  • Rush University Medical Center ( Site 0019)

    Chicago, Illinois

  • University of Chicago ( Site 0049)

    Chicago, Illinois

  • Dr. Sudarshan K. Sharma, LTD ( Site 0061)

    Hinsdale, Illinois

  • Saint Vincent Hospital and Health Center ( Site 0012)

    Indianapolis, Indiana

  • University of Iowa Hospital and Clinics ( Site 0005)

    Iowa City, Iowa

  • University of Kentucky ( Site 0045)

    Lexington, Kentucky

  • Weinberg Cancer Institute at Franklin Square ( Site 0035)

    Baltimore, Maryland

  • Saint Dominic - Jackson Memorial Hospital ( Site 0072)

    Jackson, Mississippi

  • Washington University - School of Medicine ( Site 0062)

    St Louis, Missouri

  • Nebraska Methodist Hospital ( Site 0063)

    Omaha, Nebraska

  • Dartmouth Hitchcock Medical Center ( Site 0024)

    Lebanon, New Hampshire

  • MD Anderson Cancer Center at Cooper ( Site 0067)

    Camden, New Jersey

  • Holy Name Medical Center ( Site 0037)

    Teaneck, New Jersey

  • Northwell Health- Monter Cancer Center ( Site 0075)

    Lake Success, New York

  • Sanford Roger Maris Cancer Center ( Site 0082)

    Fargo, North Dakota

  • Miami Valley Hospital [Dayton, OH] ( Site 0073)

    Centerville, Ohio

  • Oncology/Hematology Care Clinical Trials, LLC ( Site 8001)

    Cincinnati, Ohio

  • The Bing Cancer Center ( Site 0044)

    Columbus, Ohio

  • OSU Wexner Medical Center ( Site 0076)

    Hilliard, Ohio

  • Women and Infants Hospital [Providence, RI] ( Site 0039)

    Providence, Rhode Island

  • Sanford Gynecology Oncology ( Site 0004)

    Sioux Falls, South Dakota

  • Texas Oncology, P.A. - Bedford ( Site 8005)

    Bedford, Texas

  • Texas Oncology-Dallas Presbyterian Hospital ( Site 8004)

    Dallas, Texas

  • Parkland Hospital ( Site 0081)

    Dallas, Texas

  • UT Southwestern Medical Center ( Site 0046)

    Dallas, Texas

Showing 40 of 227 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.